The Predictors of COVID-19 Immunogenicity Elicited by Vaccines Against SARS-CoV-2 in Stem Cell Transplant Recipients

Basit Öğe Kaydı
dc.authoridAnkarali, Handan Camdeviren/0000-0002-3613-0523
dc.authoridErdem, Hakan/0000-0002-6265-5227
dc.authoridErturk, Umran Sumeyse/0000-0001-6493-197X
dc.authoridKaynar, Leylagul/0000-0002-2035-9462
dc.authoridSipahi, Oguz Resat/0000-0002-1243-2746
dc.authoriddelos reyes, clark steven/0009-0003-3464-1762
dc.contributor.authorElbahr, Umran
dc.contributor.authorErdem, Hakan
dc.contributor.authorAnkarali, Handan
dc.contributor.authorReyes, Clark Steven Delos
dc.contributor.authorPastrana, Jennie
dc.contributor.authorVineeth, Chithra
dc.contributor.authorHejres, Suha
dc.date.accessioned2024-08-31T07:46:39Z
dc.date.available2024-08-31T07:46:39Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: The literature falls short in providing thorough investigations into the influence of COVID-19 vaccination among those undergoing hematopoietic stem cell transplantation (HSCT). Materials and Methods: This prospective study evaluates COVID-19 antibody levels in HSCT recipients. The HSCT patients, having undergone transplantation at least three months prior, received BNT162b2 mRNA, Gam-COVID-Vac adenoviral, or BBIBP-CorV inactivated vaccines. Blood samples were taken 2-24 weeks post second dose. Results: The study involved 28 participants, comprising nine allogeneic-HSCT and 19 autologous-HSCT recipients. Among them, 18 (64.2%) exhibited positive results in SARS-CoV-2 neutralizing antibody tests, occurring at a median of 10.5 weeks (ranging from 2 to 24 weeks). In multivariate logistic regression analysis, age and a higher Charlson Comorbidity Index emerged as statistically significant variables linked with suboptimal antibody responses. Interestingly, no significant disparities surfaced in terms of anti-SARSCoV-2 spike, SARS-CoV-2 (IgG + neutralizing) antibodies, and SARS-CoV-2 (neutralizing) antibodies titers across various vaccine types and transplantation modes. However, the anti-SARS-CoV-2 nucleocapsid titers demonstrated a significant increase in patients who received the BBIBP-CorV inactivated vaccine (Sinopharm, China). Moreover, within the non -vaccinated BMT subgroup, a slightly higher yet insignificant incidence of COVID-19 was observed in comparison to the vaccinated subgroup (2/28-7.1% vs. 3/11-27.2%, p= 0.125). During the six-month post -vaccination follow-up, COVID-19 incidence was 144.9 per 1000 patient -years in the vaccinated group, contrasting with 545.4 per 1000 patient -years in the unvaccinated group. Hence, a substantial vaccination efficacy of 73.4% was noted. No fatalities were reported among either vaccinated or unvaccinated HSCT patients who contracted COVID-19 during the 30 -day follow-up period. Conclusion: The inactivated vaccine demonstrated antibody responses comparable to the Pfizer-BioNTech vaccine.en_US
dc.identifier.doi10.5578/flora.202402994
dc.identifier.endpage268en_US
dc.identifier.issn1300-932X
dc.identifier.issn2602-2842
dc.identifier.issue2en_US
dc.identifier.startpage259en_US
dc.identifier.trdizinid1242417en_US
dc.identifier.urihttps://doi.org/10.5578/flora.202402994
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1242417
dc.identifier.urihttps://hdl.handle.net/11454/104156
dc.identifier.volume29en_US
dc.identifier.wosWOS:001258536800010en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherBilimsel Tip Yayinevien_US
dc.relation.ispartofFlora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240831_Uen_US
dc.subjectAntibodyen_US
dc.subjectStem Cell Transplantationen_US
dc.subjectCovid-19en_US
dc.subjectHematologyen_US
dc.subjectVaccineen_US
dc.titleThe Predictors of COVID-19 Immunogenicity Elicited by Vaccines Against SARS-CoV-2 in Stem Cell Transplant Recipientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu